Autolus Therapeutics plc (AUTL) got a significant boost on Tuesday after the U.K.'s National Institute for Health and Care Excellence (NICE) published draft guidance recommending the company's Aucatzyl (obecabtagene autoleucel, or obe-cel) for use in the National Health Service. The recommendation covers adult patients aged 26 years and older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, often abbreviated as r/r B-ALL.
For context, acute lymphoblastic leukemia is a cancer that attacks the blood and bone marrow, causing the body to overproduce immature lymphocytes, which are a type of white blood cell. When the disease relapses or doesn't respond to standard treatments, options become limited, making therapies like Aucatzyl particularly important.
The draft recommendation sets the stage for broad patient access. Aucatzyl will be available through routine commissioning by the NHS, meaning it won't be relegated to special funding pathways that can slow down availability. Autolus said it plans to launch Aucatzyl in England and Wales imminently, and the company is also pursuing patient access through the Scottish Medical Consortium to extend coverage across the U.K.
This approval recommendation follows the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) granting conditional marketing authorization for Aucatzyl back in April 2025. That authorization was grounded in results from the FELIX study, which evaluated the therapy in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Technically speaking, obecabtagene autoleucel is an autologous CD19 CAR T cell therapy featuring a proprietary CD19 CAR. In simpler terms, it's a personalized treatment that takes a patient's own immune cells, engineers them to recognize and attack cancer cells bearing the CD19 protein, and then infuses them back into the patient.
